Anemia Management in Chronic Kidney Disease

Introduction to ESA Therapy

The National Comprehensive Cancer Network (NCCN) guidelines recommend a 300 mcg fixed dose of darbepoetin alfa every 3 weeks as an acceptable alternative dosing regimen, which maintains effective hemoglobin levels with less frequent administration compared to traditional ESAs 1
For patients with CKD not on dialysis, subcutaneous administration is the preferred route 2
The American Society of Nephrology suggests using ESAs to treat anemia in CKD patients, with a target hemoglobin range of 10-12 g/dL, and iron supplementation is necessary to ensure adequate iron stores 3

The goal is to achieve the lowest hemoglobin level that avoids transfusion necessity, and dose adjustments should be made to reduce the dose by 25% if hemoglobin increases >1 g/dL in any 2-week period, with a target rate of hemoglobin increase of 1-2 g/dL per month 2
If inadequate response after 8-9 weeks despite adequate iron stores, evaluate for other causes of ESA resistance 1
Regular monitoring of hemoglobin levels is necessary to ensure they remain within the target range, with monthly monitoring recommended, and weekly monitoring initially, to evaluate for underlying causes of ESA resistance 3, 4
Evaluation for iron deficiency, infection/inflammation, chronic blood loss, folate or vitamin B12 deficiency, and malnutrition is recommended if hemoglobin response diminishes 5

The target hemoglobin range for patients with CKD on ESA therapy is 10-12 g/dL, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, to minimize cardiovascular risks 3, 4
Exceeding 12 g/dL can increase cardiovascular risks, and aiming for normal hemoglobin levels (>13 g/dL) is not recommended, as it increases cardiovascular risks without additional benefits 4
ESA therapy should be initiated when hemoglobin is sustained below 10 g/dL after correcting other reversible causes of anemia, as recommended by the National Kidney Foundation 4

Maintaining TSAT ≥20% and ferritin ≥100 ng/mL is necessary to ensure adequate iron availability for effective erythropoiesis, as recommended by the American Journal of Kidney Diseases 5
Inadequate iron is the most common cause of poor ESA response, and TSAT and ferritin levels should be obtained if not recently checked, to confirm adequate iron stores before and during treatment 5, 4

Monitor blood pressure carefully as hypertension may develop or worsen with ESA therapy, and be aware of the increased cardiovascular risks associated with ESA therapy 2
Optimal blood pressure control is essential before and during ESA therapy to minimize cardiovascular risks, and vigilant assessment for signs/symptoms of thrombosis is crucial 4
The National Kidney Foundation recommends evaluating iron status, ruling out other causes of anemia, and assessing baseline hemoglobin level and kidney function before initiating treatment, with transplant recipients having increased risk of transplant renal artery stenosis with ESA use, and patients with failing allografts having increased hypertension with ESA use 6

HIF-PHIs, such as roxadustat, vadadustat, and daprodustat, are emerging as alternative treatments for anemia in CKD, with a different mechanism of action than ESAs, and may have different cardiovascular safety profiles, according to large clinical trials that have demonstrated their efficacy in maintaining target hemoglobin levels 3